SEVENFACT [coagulation factor VIIa (recombinant)-jncw] for Hemophilia A&B w/ Inhibitors

US WorldMeds/HEMA Biologics

SEVENFACT [coagulation factor VIIa (recombinant)-jncw] is indicated for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors. SEVENFACT is not indicated for the treatment of patients with congenital Factor VII deficiency. DoD Uniform-Formulary. SEVENFACT 225 --Rapid effect: At 3 hours, 84% of mild/moderate bleeding episodes were controlled with a single dose --Predictable response: At 9 hours, 84% of mild/moderate bleeding episodes treated achieved bleed control after a single dose --Reliable control: At 24 hours, 99.5% of mild/moderate bleeding episodes were resolved --Convenient home use: 98% of bleeding episodes were treated at home